12 February 2015
GODDYN has advised TiGenix (Euronext Brussels: TIG) on an agreement with Lonza for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease. TiGenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases. Lonza is a global leader in biological and cell therapy manufacturing. TiGenix and Lonza announced today an agreement for…
Read More
1 January 2015
GODDYN further strengthens its legal work for TiGenix (external link). TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programmes. Bart GODDYN (through GODDYN BVBA) will continue to cover a broad range of legal matters relevant to the bio-tech industry with a special focus on transactional and advisory work for TiGenix’s R&D, clinical,…
Read More
17 October 2014
On 16 October 2014, Bart GODDYN spoke about industry perspectives of research & development contracts at the seminar of the European Academy for Taxes, Economics & Law in Berlin, Germany. Bart was invited for the eighth time as a speaker for this biannual conference. Topics included trade secrets, confidentiality, material transfer, intellectual property ownership and licensing.
